Evaluation of PPAR-α, PPAR-γ, TLR2, TLR4 Gene Expression In Patients with Coronary Artery Disease (CAD): An Experimental Study

冠状动脉疾病(CAD)患者PPAR-α、PPAR-γ、TLR2、TLR4基因表达的评估:一项实验研究

阅读:1

Abstract

BACKGROUND: Coronary artery disease (CAD) is one of the heart diseases that causes the death of many patients in the world. Many genes and molecular pathways are involved in the regulation of inflammation. However, some genes have a regulatory role and control immune responses. In recent studies, few studies have been done regarding the role of TLRs and PPARs in CAD. Hence, the present study aimed to determine and compare the mRNA expression of PPAR-α and PPAR-γ genes and genes of the innate immune system messenger pathway, including TLR2and TLR4, in CAD patients in comparison to normal individuals. METHODS: This study (case-control) was conducted on 12 patients with coronary arteries and 10 healthy individuals as healthy controls. RNA extraction was performed, cDNA was produced, and then the mRNA expression levels of TLR2, TLR4, PPAR-α, and PPAR-γ genes were examined using Syber green Real-Time PCR. The t-test sample and the related non-parametric tests were used to investigate the relationship between the quantitative variables. The significance level in all tests was considered as less than 0.05. RESULTS: The results of data analysis showed that the expression level of TLR2 and TLR4 genes was significantly increased in the patient group compared to the controls (P=0.001). However, although PPAR-α and PPAR-γ genes were up-regulated in patients' samples, the comparison of gene expression levels did not significantly differ between the case and control groups. CONCLUSION: we found meaningful results to the significant role of 2 and TLR4 in the pathogenesis of CAD and emphasize the hypothesis that TLR2 and TLR4 can be considered therapeutic options.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。